Amgen Inc (AMGN)vsBarrick Mining Corporation (B)
AMGN
Amgen Inc
$353.93
+1.58%
HEALTHCARE · Cap: $187.83B
B
Barrick Mining Corporation
$37.69
+1.48%
BASIC MATERIALS · Cap: $62.59B
Smart Verdict
WallStSmart Research — data-driven comparison
Amgen Inc generates 117% more annual revenue ($36.75B vs $16.96B). B leads profitability with a 29.4% profit margin vs 21.0%. B appears more attractively valued with a PEG of 2.04. B earns a higher WallStSmart Score of 81/100 (A-).
AMGN
Strong Buy70
out of 100
Grade: B-
B
Exceptional Buy81
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.8%
Fair Value
$665.50
Current Price
$353.93
$311.57 discount
Margin of Safety
+65.3%
Fair Value
$137.12
Current Price
$37.69
$99.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 106 in profit
Strong operational efficiency at 30.5%
Earnings expanding 112.1% YoY
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Strong operational efficiency at 52.6%
Revenue surging 64.5% year-over-year
Earnings expanding 150.0% YoY
Large-cap with strong market position
Every $100 of equity generates 21 in profit
Keeps 29 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Trading at 22.0x book value
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, EPS Growth. Profitability is solid with margins at 21.0% and operating margin at 30.5%.
Bull Case : B
The strongest argument for B centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 29.4% and operating margin at 52.6%. Revenue growth of 64.5% demonstrates continued momentum.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book.
Bear Case : B
The primary concerns for B are PEG Ratio.
Key Dynamics to Monitor
AMGN profiles as a mature stock while B is a growth play — different risk/reward profiles.
B carries more volatility with a beta of 1.00 — expect wider price swings.
B is growing revenue faster at 64.5% — sustainability is the question.
B generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
B scores higher overall (81/100 vs 70/100), backed by strong 29.4% margins and 64.5% revenue growth. AMGN offers better value entry with a 46.8% margin of safety. Both earn "Exceptional Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Barrick Mining Corporation
BASIC MATERIALS · GOLD · USA
Barnes Group Inc. provides engineering products, industrial technologies, and solutions in the United States and internationally. The company is headquartered in Bristol, Connecticut.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?